CONFERENCE AGENDA

 

 

Singapore, 8 - 9 December 2020

Schedule

Create your personal agenda –check the favourite icon

Dec 811:30
Conference pass

Panel: Asia's immunotherapy landscape and lessons learned from international successes

Immunotherapy
Dec 811:30
Conference pass

Enleofen Bio: First-in-class Therapeutics for Fibro-inflammatory Diseases

Clinical Trials
Dec 811:30
Conference pass

Neurotech: the next frontier

Pharma 4.0
Charles Stacey, President And Chief Executive Officer, CERECINSingapore
Dec 811:30
Conference pass

Moving from market access to patient access from a payer's perspective

Market Access & Pricing
Anand Jha, Managing Director, Ansea Consultants Pte LtdSingapore
Dec 811:30
Conference pass

Advances in precision medicine: Role of AI

Bio Data
Rajiv Rana, Regional Medical Director Asia Pacific, Merck Pte. Ltd.Singapore
Dec 811:30
Conference pass

Panel: Bio-Entrepreneur Journey - Trials and Tribulations on the Path to Success

Biotech Invest
Yen Choo, Associate Professor, Lee Kong Chian School of MedicineSingapore
Anthony Desir, Director, MoexaHong Kong
Dec 811:40
Conference pass

Utility of AI and big data in drug development

Bio Data
Vishal Doshi, Chief Executive Officer, AUM BiosciencesSingapore
Dec 811:50
Conference pass

CURATE.AI: Finding the optimal drugs and dosage

Pharma 4.0
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Dec 811:50
Conference pass

Using AI and data for diagnosis

Bio Data
Weimiao YU, Chief Technology Officer, A!maginostic Pte. Ltd.Singapore
Dec 812:10
Conference pass

Humanized mouse model: A tool to address human specific questions in biomedical research

Clinical Trials
Qingfeng Chen, Principal Investigator, A-starSingapore
Dec 812:10
Conference pass

How AI is creating opportunities for pharma

Pharma 4.0
Vikram Shetty, Country Medical Lead, PfizerSingapore
Dec 812:10
Conference pass

Making antibodies affordable for all

Market Access & Pricing
Pritha Aggarwal, Senior Program Specialist, IAVIIndia
Dec 812:10
Conference pass

Next generation of artificial intelligence for drug discovery

Bio Data
Dec 812:10
Conference pass

Biotech Pitch

Biotech Invest
James Garner, Chief Executive Officer And Managing Director, Kazia Therapeutics LimitedAustralia
Dec 812:20
Conference pass
Dec 812:30
Conference pass

Biotech Pitch

Biotech Invest
Adrian Joseph, Director, Biogenes Technologies Sdn BhdMalaysia
Tang Kok Mun, Director, Biogenes Technologies Sdn BhdMalaysia
Dec 812:40
Conference pass

Biotech Pitch

Biotech Invest
Yong Wei Shian, Co-Founder And Chief Executive Officer, Advanx HealthMalaysia
Dec 812:50
Conference pass

Biotech Pitch

Biotech Invest
Bill Tsai, Chief Marketing Officer, MedFluid Co LtdTaiwan
Dec 814:00
Conference pass

Innovating drug discovery with AI

Keynotes
Chris Gibson, Chief Executive Officer And Co-Founder, Recursion PharmaceuticalsUnited States
Dec 814:00
Conference pass

Panel: Accessing capital for scaling up your biotech

Biotech Invest
Sridhar Gopal, Head of Business Development, AbbVieUnited States
Da Liu, Managing Director, China Resources Life Science FundHong Kong
Dec 815:10
Conference pass

Biotech Pitch

Biotech Invest
Alexandre Civiere, Project Manager, CellProthera Pte LtdSingapore
Dec 815:40
Conference pass

Moving from conventional clinical trials to adaptive clinical trials

Clinical Trials
John Patava, Chief Operating Officer, AUM BiosciencesSingapore
Dec 815:40
Conference pass
Dec 815:40
Conference pass

Panel: Real world evidence - Driving a new drug development paradigm

Market Access & Pricing
Dec 815:40
Conference pass

Using bioinformatics tools to study the genomic profile for personalised medicine

Bio Data
Dec 816:00
Conference pass

Panel: Partnering for the next immuno-oncology breakthrough

Immunotherapy
Stefan Hart, Senior Director, Scientific Innovation Oncology, J&J Innovation CentreSingapore
Dec 816:00
Conference pass

Challenges in development of biosimilars and biosimilarity assessment - statistical perspective

Clinical Trials
Sophie Tsou, Associate Investigator, Division Of Biostatistics And Bioinformatics, National Health Research InstitutesTaiwan
Dec 816:00
Conference pass

Synthetic DNA technologies enable antibody discovery and optimization

Pharma 4.0
Dec 816:00
Conference pass

Panel: Attracting early stage capital: What are VCs looking for in biotech investments in Asia?

Biotech Invest
Rohit Pratap Singh, Vice President, Xeraya Capital Sdn BhdMalaysia
Gavin Teo, General Partner, B Capital GroupUnited States
Dec 816:20
Conference pass

Adaptive designs in early clinical studies

Clinical Trials
Dec 816:20
Conference pass

Accelerating antibody engineering and discovery using synthetic libraries

Pharma 4.0
Cedric Wu, Vice President Of R&D, GenScriptUnited States
Dec 816:20
Conference pass

Current and future applications of bioinformatics in pharma

Bio Data
Dec 816:40
Conference pass

Driving immuno-oncology with rational antibody discovery

Immunotherapy
Dec 816:40
Conference pass

Panel: Clinical trials in China

Clinical Trials
Moderator: Judith Walker, Chief Medical Officer, CERECINSingapore
Daniel Liu, Chief Scientific Officer, Beijing Clinical Service Center
Da Liu, Managing Director, China Resources Life Science FundHong Kong
Dec 816:40
Conference pass

Integrating machine learning and combinatorial CRISPR for drug development for the precision medicine paradigm

Pharma 4.0
Jeffrey Lu, Co-Founder And Chief Executive Officer, Engine BiosciencesUnited States
Dec 816:40
Conference pass

Forming a collaborative relationship with stakeholders and payers

Market Access & Pricing
Shailendra Bajpai, Global Head Of Disease Management And Key Stakeholder Engagement, Sanofi-Aventis Singapore Pte LtdSingapore
Dec 816:40
Conference pass

Biocomputational design of synthetic antibodies for molecular applications

Bio Data
Tang Kok Mun, Director, Biogenes Technologies Sdn BhdMalaysia
Dec 816:50
Conference pass

Biotech Pitch

Biotech Invest
Hossein Nejati, Co-Founder And Chief Technology Officer, KroniKareSingapore
Dec 817:00
Conference pass

Changing paradigms in drug discovery - combining robotics and AI

Pharma 4.0
Dec 817:20
Conference pass

Molecular insights into key mechanistic steps of an adaptive immune response

Immunotherapy
Dec 817:20
Conference pass

Singapore's cancer clinical trials ecosystem - Challenges and solutions for stakeholders

Clinical Trials
Dec 817:20
Conference pass

Challenges and regulatory considerations in development of complex generics

Pharma 4.0
Dec 817:20
Conference pass

Biotech Pitch

Biotech Invest
Weimiao YU, Chief Technology Officer, A!maginostic Pte. Ltd.Singapore
Dec 89:20
Conference pass

Keynote Panel: The digital opportunity for pharma - New technology, new investments, new opportunities

Keynotes

Create your personal agenda –check the favourite icon

Dec 909:20
Conference pass

Keynote Panel: Fostering innovation through partnerships

Keynotes
Anand Gautam, Senior Director And Head, External Science And Innovation, Anz And Sea, PfizerAustralia
Damian O'Connell, Chief Executive Officer Experimental Drug Development Centre, A Star - Agency For Science Technology And ResearchSingapore
Dec 911:40
Conference pass

Drug development – critical need to move beyond single agent therapy

Immunotherapy
Dec 911:40
Conference pass

How to coordinate remote inspection - TGA PV inspection

Clinical Trials
Dec 911:40
Conference pass
Dec 912:00
Conference pass

Panel: Partnering to improve quality in clinical trials

Clinical Trials
Sunil Pandita, Manager Clinical Quality Assurance, Abbott LabSingapore
Hyejin Shin, Director, Group Leader, Clinical Qa, Samsung BioepisRepublic Of Korea
Dec 912:00
Conference pass

Panel: Partnering for the future

Pharma 4.0
James Garner, Chief Executive Officer And Managing Director, Kazia Therapeutics LimitedAustralia
Dec 914:00
Conference pass

The progression of Car-T Therapy in clinical settings

Immunotherapy
Aung Myo, Vice President, Clinical Development, Tessa TherapeuticsSingapore
Dec 914:00
Conference pass

Tissue chips to inform clinical trial design and implementation in precision medicine

Clinical Trials
Danilo A Tagle, Associate Director, National Center For Advancing Translational SciencUnited States
Dec 914:00
Conference pass

Improving patient engagement with digital therapeutics

Pharma 4.0
Dec 914:00
Conference pass

Panel: Fostering homegrown innovation in Southeast Asia - investor & biotech perspectives

Biotech Invest
Moderator: Ogan Gurel, Chief Scientific Officer, Frt, Chief Marketing Officer, Eidware, Soundmind And Visiting Professor, D.G.I.S.T.Republic Of Korea
Dec 914:20
Conference pass

LioCyx™ : Cell therapy in Asia – Current and future plans

Immunotherapy
Stephen Lim, Chief Executive Officer, Lion TCR Pte LtdSingapore
Dec 914:20
Conference pass

Panel: Transforming clinical trials with technology

Clinical Trials
Dec 914:40
Conference pass

Application of NK cell and T cell therapy for the treatment of cancer

Immunotherapy
Sarmistha Deb, CSO, DiponEd BioIntelligenceIndia
Dec 915:00
Conference pass

Global industry adopted clinical project management competencies

Clinical Trials
Dec 915:00
Conference pass

How technology is creating new opportunities for patient centricity

Pharma 4.0
Khee Suan Bang, Clinical Study Manager, Digital And Real-World Evidence, Danone Nutricia ResearchSingapore
Dec 915:20
Conference pass
Dec 915:20
Conference pass

Personalised Healthcare - Building the next frontier today

Pharma 4.0
Jek Fong, Head Of Market Access, RocheSingapore
Dec 915:40
Conference pass

How innovation is driving patient centricity: Japan and other perspectives

Pharma 4.0
last published: 10/Jun/20 01:56 GMT

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738